News & Events

News &

TRS01 Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual meeting

November 8, 2021

TEL AVIV, Israel, November 8, 2021 — Tarsier Pharma, an advanced clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced that its GADOT 20/20 Phase I/II results in TRS01 eyedrops for uveitis, will be presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting, taking place in New Orleans and virtually, Nov. 12-15, 2021.

GADOT 20/20 was a dose-ranging, randomized, double-masked, controlled phase I/II clinical trial that evaluated the safety and efficacy of TRS01 eyedrops in 16 subjects with active non-infectious anterior uveitis in the U.S. Results showed a statistically significant improvement in the signs and symptoms of the disease, with the high-dose usage being superior to low-dose in a few important measures, such as Anterior Chamber Cells (ACC) clearance, pain resolution, and visual acuity improvement.

Dr. Ron Neumann, Tarsier’s Chief Medical Officer, said: “We are excited to present the GADOT 20/20 trial results at the American Academy of Ophthalmology 2021 Annual Meeting. We are looking forward to spreading the word about TRS01 to the Ophthalmic community, and raising the interest in our ongoing studies.  We hope in the future to also present our phase-3 results at this important conference “.

Dr. David S Chu, a uveitis expert from New Jersey who participated in the study as Principal Investigator, will present GADOT 20/20’s results in a poster discussion, that will be available on-demand:

Title: TRS01, a Novel Nonsteroidal Treatment of Active Noninfectious Anterior Uveitis: Results of a Phase 1/2 clinical trial.

Poster Number: PO112.

Session: PD13 – Uveitis Poster Discussion.

About Tarsier Pharma

Tarsier Pharma is phase-3 pharmaceutical company, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular blinding diseases. TRS is a bio-inspired breakthrough proprietary technology platform, based on a new chemical entity with novel mechanism of action, that demonstrated safety and efficacy in a rare debilitating and blinding indication.

Lead product candidate for uveitic glaucoma

Non-infectious uveitis is an autoimmune blinding ocular inflammation, considered the third leading cause of blindness in the developed world. Tarsier’s TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – that is considered an end-stage condition of uveitis. Once a uveitis patient has also developed glaucoma (uveitic glaucoma), the only available treatments for active inflammation, which are steroids, should be avoided due to their side effects of expediting glaucoma and vision loss. Thus, TRS01 has the potential to become the standard of care for uveitic glaucoma.

Scroll to Top